Publications
Scientific publications
A selection of scientific articles directly related to our work on Targeted Active Therapy and complementary peptides for autoimmune diseases.
Complementary peptide · Myasthenia gravis
- 01
Study on therapeutic peptide immunization for canine myasthenia gravis
Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue
Galin FS, Chrisman CL, Cook JR, Xu L, Jackson PL, Noerager BD, et al. Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Brain Behav Immun. 2007 Mar;21(3):323–31. doi:10.1016/j.bbi.2006.10.001 PubMed PMID: 17113748; PubMed Central PMCID: PMC1857319.
PubMed 17113748 - 02
Remission rates with current treatment for canine myasthenia gravis
Case series of canine myasthenia gravis: a classification approach with consideration of seronegative dogs
Dos Santos RX, Waelkens J, Crawford AH, Khan S, Sami S, Gomes SA, et al. Case series of canine myasthenia gravis: a classification approach with consideration of seronegative dogs. J Vet Intern Med. 2025 May 1;39(3):jvim70113. doi:10.1111/jvim.70113
PubMed 40298067 - 03
Rational design of complementary peptide immunizations for autoimmune disease
Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network
Weathington NM, Blalock JE. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev Vaccines. 2003 Feb;2(1):61–73. doi:10.1586/14760584.2.1.61 PubMed PMID: 12901598.
PubMed 12901598 - 04
Using reverse hydropathy to address autoimmune diseases
Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity
Hardison MT, Blalock JE. Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity. Front Biosci (Elite Ed). 2012 Jan 1;4(5):1864–70. doi:10.2741/e508 PubMed PMID: 22202003; PubMed Central PMCID: PMC4107873.
PMC PMC4107873 - 05
Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells
Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells
Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells. Cellular Immunology. 2001 Mar 15;208(2):107–14. doi:10.1006/cimm.2001.1777
ScienceDirect - 06
The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis
The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis
McAnally JL, Xu L, Villain M, Blalock JE. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Experimental Biology and Medicine. 2001 Apr 1;226. doi:https://doi.org/10.1177/153537020122600407
DOI 10.1177/153537020122600407 - 07
A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help
A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help
Araga S, Xu L, Nakashima K, Villain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J. 2000 Jan;14(1):185–96. doi:10.1096/fasebj.14.1.185 PubMed PMID: 10627293
PubMed 10627293 - 08
Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors
Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors
Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J Immunol. 1996 Jul 1;157(1):386–92. PubMed PMID: 8683141.
PubMed 8683141 - 09
Use of Complementary Peptides and Their Antibodies in B-Cell-Mediated Autoimmune Disease: Prevention of Experimental Autoimmune Myasthenia Gravis with a Peptide Vaccine
Use of Complementary Peptides and Their Antibodies in B-Cell-Mediated Autoimmune Disease: Prevention of Experimental Autoimmune Myasthenia Gravis with a Peptide Vaccine
Araga S, Blalock JE. Use of Complementary Peptides and Their Antibodies in B-Cell-Mediated Autoimmune Disease: Prevention of Experimental Autoimmune Myasthenia Gravis with a Peptide Vaccine. ImmunoMethods. 1994 Oct 1;5(2):130–5. doi:10.1006/immu.1994.1047
ScienceDirect - 10
Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor
Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor
Araga S, LeBoeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proceedings of the National Academy of Sciences. 1993 Sep 15;90(18):8747–51. doi:10.1073/pnas.90.18.8747
PubMed 8378359
Complementary peptide · Multiple sclerosis
- 11
An IgM anti-MBP Ab in a case of Waldenstrom macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE
An IgM anti-MBP Ab in a case of Waldenstrom macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE
Noerager BD, Inuzuka T, Kira J, Blalock JE, Whitaker JN, Galin FS. An IgM anti-MBP Ab in a case of Waldenstrom’s macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE. J Neuroimmunol. 2001 Feb 1;113(1):163–9. doi:10.1016/s0165-5728(00)00425-2 PubMed PMID: 11137588.
PubMed 11137588 - 12
Highly related immunoglobulin light chain sequences in different multiple sclerosis patients
Highly related immunoglobulin light chain sequences in different multiple sclerosis patients
Blalock JE, Zhou SR, Maier CC, Galin FS, Whitaker JN. Highly related immunoglobulin light chain sequences in different multiple sclerosis patients. J Neuroimmunol. 1999 Dec;100(1–2):98–101. doi:10.1016/s0165-5728(99)00188-5 PubMed PMID: 10695719.
PubMed 10695719 - 13
Active immunization with complementary peptide PBM 9-1: preliminary evidence that it modulates experimental allergic encephalomyelitis in PL/J mice and Lewis rats
Active immunization with complementary peptide PBM 9-1: preliminary evidence that it modulates experimental allergic encephalomyelitis in PL/J mice and Lewis rats
Zhou SR, Whitaker JN. Active immunization with complementary peptide PBM 9-1: preliminary evidence that it modulates experimental allergic encephalomyelitis in PL/J mice and Lewis rats. J Neurosci Res. 1996 Aug 15;45(4):439–46. doi:10.1002/(SICI)1097-4547(19960815)45:4%3C439::AID-JNR13%3E3.0.CO;2-W PubMed PMID: 8872904.
PubMed 8872904 - 14
Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies
Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies
Zhou SR, Whitaker JN. Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol. 1993 Feb 15;150(4):1629–42. PubMed PMID: 7679432.
PubMed 7679432
Complementary peptide · Guillain-Barré syndrome
- 15
A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
Araga S, Kishimoto M, Doi S, Nakashima K. A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats. J Immunol. 1999 Jul 1;163(1):476–82. PubMed PMID: 10384151.
PubMed 10384151
A scientific question?
Our team and our scientific advisory board are available to address any scientific questions you may have. Please feel free to contact us.